Option chain shows key data for Vivos Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Vivos Therapeutics.

Vivos Therapeutics (NASDAQ:VVOS) Stock, Option Chain

Vivos Therapeutics

Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.

Rivian, Draftkings, Block, Pinterest, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

AIEV

ALUR

ARBK

BMRA

BSLK

DPRO

EHGO

IFBD

JCSE

KULR

MNSO

MOND

PRZO

RGTI

SGBX

STLA

TDTH

VMAR

VVOS

Why Vision Marine Technologies Shares Are Trading Higher By 34%; Here Are 20 Stocks Moving Premarket

Crude-oil-4-logo

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

EWTX

INTC

MBLY

PGNY

Crude Oil Gains Over 1%; Mobileye Global Shares Jump

xr:d:DAFmiHkAheY:2,j:3947799284260130445,t:23062208

Earnings

Dow Jumps Over 500 Points; FactSet Research Posts Upbeat Earnings

Vivos Therapeutics Inc

Press Releases

Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

General

Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

FDA Approval Sends Shares of this Healthcare Company Higher

Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Health Care

Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association

Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call

Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update

Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Vivos Therapeutics to Participate in Fireside Chat with Water Tower Research on February 18, 2025 at 12:00 pm ET.

Vivos Therapeutics Expands Strategic Alliance in Colorado and Seeks New Sleep Center Affiliations and Acquisitions Nationwide

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

American Shared Hospital Services Common Stock

American Shared Hospital

Biodesix

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Concord Medical Services

Enzo Biochem, Inc. Common Stock ($0.01 Par Value)

Enzo Biochem

Euda Health Holdings Limited - Ordinary Shares

EUDA Health Holdings

Kindly MD

23andMe Holding

Mobile-health Network Solutions - Class A Ordinary Shares

Mobile-health Network

ModivCare

MSP Recovery, Inc. - Class A Common Stock

MSP Recovery

NewGenIvf Group Limited - Class A Ordinary Shares

NewGenIvf Group

Ontrak

Performant Healthcare, Inc. - Common Stock

Performant Healthcare

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners

Prenetics Global Limited - Class A Ordinary Share

Prenetics Global

Precipio

SHL Telemedicine Ltd - American Depositary Shares

SHL Telemedicine

Syra Health

Ascendiant Capital

Alliance Global Partners

Comments

Vivos Therapeutics

Vivos Therapeutics (VVOS) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga